Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer.
Eighty patients with advanced metastatic renal cancer have been treated with hormones, chiefly medroxyprogesterone acetate (Provera). This progestational compound is remarkably free from side-effects and can be given in high dosage for long periods without serious complications. Ninety per cent of cases had multiple metastases: in 76% more than one organ was involved and nearly 50% were seriously ill or "terminal".Subjective improvement occurred in at least 55%. In 11 patients there was marked improvement in the radiological or clinical signs of tumour within 2 to 6 weeks of commencing treatment or changing to a different hormone. In two further cases improved general health was associated with stationary metastases for 20 months. A significant objective response occurred in 16% of the total series. A favourable response was seen more often in men (21%) than in women (8%). If deaths within 6 weeks are excluded the objective response rate in men is increased to 27%. Although the response of advanced renal cancer to hormonal treatment is usually incomplete and of brief duration, it is possible for such treatment to offer a "new lease of life" to a seriously ill patient, even in old age, for 2 to 3 years.
D000008:Abdominal Neoplasms / Q000188:drug therapy; D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D012737:Sex Factors; D013727:Terminal Care; D013739:Testosterone / Q000627:therapeutic use
D013739:Testosterone; D008525:Medroxyprogesterone